Retraction of a JACC study, industry influence on dietary data, TAVR valves and thrombosis, nonstroke risks of AF, and exercise and alcohol are discussed in this week's podcast.

Dr Mandrola interviews the principal investigator of a new study showing that long-term low systolic blood pressure and LDL cholesterol dramatically reduces the risk for CV events.

Trends in infective endocarditis, vein-graft intervention, use of OCT in ACS, hypertrophic cardiomyopathy, and electronic health records are discussed in this week's podcast.

Trials from the 2016 ESC Congress, including DANISH, NORSTENT, PRAGUE-18, ENSURE-AF, ANNEXA-4, LDL/low-BP exposure, and CE-MARC 2 are discussed by Dr John Mandrola in this week's podcast.

UPDATED with Transcript // DANISH, SAVE, ANNEXA-4; presentations on apheresis; and four 'curiosities' in heart failure and acute coronary syndrome covering stem cells, remote monitoring, and antiplatelet therapy are discussed.

Misdiagnosis of HCM, preop frailty, remote monitoring of cardiac devices, genetic influences in type 2 DM, beta-blockers post-PCI, and the upcoming ESC meeting are discussed in this week's podcast.

PCSK9 drug pricing, medical adherence, warfarin stability, hs-troponin, brain protection during TAVR, and an FDA decision on a factor Xa antidote are discussed by Dr Mandrola in this week's podcast.

Lipid screening in kids, duration of dual antiplatelets, public reporting of PCI outcomes, AF with sepsis, INR stability, and Eric Topol's interview with Laura Esserman are discussed this week.

Picking the correct dose of apixaban, gender and AF ablation, gains in STEMI care, and data sharing are the topics discussed by Dr John Mandrola in this week's podcast.

Letting non-trialists at clinical trial data is like letting the uneducated run education, according to Dr Ohman in this discussion with Dr Harrington on open data.